Abstract:Systemic sclerosis (SSc) is a progressive, multi-organ disease with limited treatment options. While a recent proof-of-concept study using Romilkimab or SAR156597, a bi-specific IL-4/IL-13 antibody, suggests a direct role of these cytokines in the pathophysiology of SSc, their contributions to the balance between inflammation and fibrosis are unclear. Here, we determine the roles of type 2 inflammation in fibrogenesis using a Fos-related antigen 2 overexpressing transgenic mice (FRA2-Tg), which develop a spontaneous, age-dependent progressive lung fibrosis. We defined the molecular signatures of inflammation and fibrosis at three key stages in disease-progression, corresponding to pre-onset, inflammatory dominant, and fibrosis dominant biology, and revealed an early increase in cytokine-cytokine receptor interactions and antigen-processing and presentation pathways followed by enhanced Th2 and M2- macrophage driven type 2 responses. This type-2 inflammation progressed to extensive fibrotic pathology by 14-18 weeks of age with these gene signatures overlapping significantly with those seen in lungs of patients with SSc with interstitial lung disease (ILD). These changes were also evident in the histopathology which showed perivascular and peribronchiolar inflammation with prominent eosinophilia and accumulation of profibrotic M2-like macrophages followed by rapid progression to fibrosis with thickened alveolar walls with multifocal-fibrotic-bands and signs of interstitial-pneumonia. Critically, treatment with a bispecific antibody targeting IL-4 and IL-13 during the inflammatory phase abrogated the Th2 and M2-responses and led to near complete abrogation of lung fibrosis. These data recapitulate important features of fibrotic-progression in lungs of SSc-ILD patients and enhance our understanding of the progressive pathobiology of SSc. This study also further establishes FRA2-Tg mice as a valuable tool for testing future therapeutic agents in SSc-ILD.

Tenascin-C Drives Persistence of Organ Fibrosis

Systemic Sclerosis Dermal Fibroblasts Induce Cutaneous Fibrosis Through Lysyl Oxidase–like 4: New Evidence from Three‐Dimensional Skin‐like Tissues

Lysyl Oxidase Enzymes Mediate TGF-β1-induced Fibrotic Phenotypes in Human Skin-Like Tissues

Toll‐like Receptor 9 Signaling is Augmented in Systemic Sclerosis and Elicits Transforming Growth Factor Β–dependent Fibroblast Activation

Toll-Like Receptor-4 Signaling Drives Persistent Fibroblast Activation and Prevents Fibrosis Resolution in Scleroderma

FibronectinEDA promotes chronic cutaneous fibrosis through Toll-like receptor signaling

T Follicular Helper–like Cells Contribute to Skin Fibrosis

Pathogenic Roles of Autoantibodies and Aberrant Epigenetic Regulation of Immune and Connective Tissue Cells in the Tissue Fibrosis of Patients with Systemic Sclerosis

TLR8 Aggravates Skin Inflammation and Fibrosis by Activating Skin Fibroblasts in Systemic Sclerosis.

[Transforming Growth Factor-Beta and Its Receptors in Scleroderma].

The role and mechanism of CRISPLD2 in skin fibrosis of systemic sclerosis

Role of endothelin-1 in the skin fibrosis of systemic sclerosis

Targeting CD13/aminopeptidase N as a novel therapeutic approach for scleroderma fibrosis

Neutrophil-driven CD206hiMHCIIlo macrophages are critical for skin fibrosis during systemic sclerosis

Role of endoglin in fibrosis and scleroderma.

Canonical Wnt signaling induces skin fibrosis and subcutaneous lipoatrophy: A novel mouse model for scleroderma?

Cellular Transdifferentiation: A Crucial Mechanism of Fibrosis in Systemic Sclerosis

Impaired LAIR-1-mediated immune control due to collagen degradation in fibrosis

TGFβ promotes low IL10-producing ILC2 with profibrotic ability involved in skin fibrosis in systemic sclerosis

Molecular Features and Stages of Pulmonary Fibrosis Driven by Type 2 Inflammation

Immune Cell Dysregulation As a Mediator of Fibrosis in Systemic Sclerosis